

Mengzhao Wang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6810328/mengzhao-wang-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104
papers

1,256
citations

21
h-index

29
g-index

139
ext. papers

1,806
ext. citations

3.4
avg, IF

4.98
L-index

#	Paper	IF	Citations
104	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. <i>PLoS ONE</i> , 2015 , 10, e0143515	3.7	94
103	Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer. <i>Respirology</i> , 2016 , 21, 519-25	3.6	53
102	Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster. <i>Emerging Microbes and Infections</i> , 2020 , 9, 924-927	18.9	45
101	EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 1305-1310	3.5	39
100	MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. <i>OncoTargets and Therapy</i> , 2020 , 13, 2491-2510	4.4	38
99	PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. <i>Future Oncology</i> , 2018 , 14, 665-674	3.6	37
98	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. <i>OncoTargets and Therapy</i> , 2018 , 11, 6189-6196	4.4	35
97	Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. <i>EBioMedicine</i> , 2019 , 42, 304-310	8.8	33
96	Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 209-216	12.9	30
95	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 87-103	1.9	29
94	Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. <i>Nature Communications</i> , 2017 , 8, 823	17.4	29
93	Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. <i>Oncotarget</i> , 2017 , 8, 5861-5873	3.3	29
92	Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. <i>Theranostics</i> , 2016 , 6, 1232-43	12.1	28
91	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 122, 32-37	5.9	27
90	CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. <i>Future Oncology</i> , 2018 , 14, 2179-2188	3.6	26
89	Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death. <i>PLoS ONE</i> , 2015 , 10, e0139144	3.7	26
88	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020 , 11, 191-197	3.2	26

87	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. <i>Thoracic Cancer</i> , 2019 , 10, 551-556	3.2	25
86	Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1512-1522	8.9	24
85	Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2014 , 85, 401-7	5.9	23
84	Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy. <i>Oncotarget</i> , 2017 , 8, 86615-86624	3.3	21
83	Integrin Imaging with Tc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non-Small Cell Lung Cancer. <i>Radiology</i> , 2016 , 281, 958-966	20.5	21
82	Current small cell lung cancer treatment in China. <i>Thoracic Cancer</i> , 2015 , 6, 233-8	3.2	19
81	Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. <i>Cancer Management and Research</i> , 2019 , 11, 7707-7719	3.6	18
80	Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018 , 9, 640-645	3.2	17
79	Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 13136-45	1.4	17
78	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 989-999	4.4	16
77	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. <i>Lung Cancer</i> , 2018 , 125, 142-149	5.9	16
76	Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study. <i>Thoracic Cancer</i> , 2019 , 10, 1521-1532	3.2	15
75	Paraneoplastic limbic encephalitis associated with lung cancer. <i>Scientific Reports</i> , 2018 , 8, 6792	4.9	15
74	Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. <i>Lung Cancer</i> , 2018 , 122, 1-6	5.9	13
73	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019 , 16, 189-204	5.2	12
72	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9008-9008	2.2	12
71	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020 , 11, 810-818	3.2	11
70	Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine. <i>Future Oncology</i> , 2019 , 15, 2531-2542	3.6	10

69	The Prevalence and clinical characteristics of primary Sjogren's syndrome patients with lung cancer: An analysis of ten cases in China and literature review. <i>Thoracic Cancer</i> , 2015 , 6, 475-9	3.2	10
68	Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. <i>Thoracic Cancer</i> , 2020 , 11, 1068-1075	3.2	10
67	The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020 , 16, 201-210	1.9	10
66	Clinical characteristics of patients with lung cancer and idiopathic pulmonary fibrosis in China. <i>Thoracic Cancer</i> , 2012 , 3, 156-161	3.2	10
65	PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours. <i>Oncology Letters</i> , 2017 , 14, 1373-1378	2.6	10
64	Sputum Cell-Free DNA: Valued Surrogate Sample for Detection of EGFR Mutation in Patients with Advanced Lung Adenocarcinoma. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 934-942	5.1	9
63	Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. <i>Thoracic Cancer</i> , 2020 , 11, 594-602	3.2	9
62	Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature. <i>Thoracic Cancer</i> , 2018 , 9, 1788-1794	3.2	9
61	Clinical recommendations on lung cancer management during the COVID-19 pandemic. <i>Thoracic Cancer</i> , 2020 , 11, 2067-2074	3.2	8
60	Efficacy of icotinib in advanced lung squamous cell carcinoma. <i>Cancer Medicine</i> , 2018 , 7, 4456-4466	4.8	8
59	Integrated positron emission tomography and computed tomography in preoperative lymph node staging of non-small cell lung cancer. <i>Chinese Medical Journal</i> , 2014 , 127, 607-13	2.9	7
58	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020 , 11, 498-504	3.2	6
57	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 488-492	3.2	6
56	Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. <i>Thoracic Cancer</i> , 2020 , 11, 1955-1962	3.2	5
55	Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018 , 9, 1056-1061	3.2	5
54	The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20613-e20613	2.2	5
53	Risk factors for immune-related adverse events: what have we learned and what lies ahead?. <i>Biomarker Research</i> , 2021 , 9, 79	8	5
52	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association. <i>Cancer Biology and Medicine</i> , 2020 , 17, 896-909	5.2	5

51	Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 357-363	3.2	5
50	Clinicopathological features of lung cancer in patients with rheumatoid arthritis. <i>Journal of Thoracic Disease</i> , 2018 , 10, 3965-3972	2.6	5
49	Renal immune-related adverse events of immune checkpoint inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020 , 16, 305-311	1.9	4
48	Histologic transformation of lung cancer during pembrolizumab therapy: A case report. <i>Thoracic Cancer</i> , 2020 , 11, 793-796	3.2	4
47	Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. <i>Clinical Respiratory Journal</i> , 2020 , 14, 1131-1136	1.7	4
46	Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020 , 16, 299-304	1.9	4
45	Thymic neoplasms patients complicated with bronchiectasis: Case series in a Chinese hospital and literature review. <i>Thoracic Cancer</i> , 2019 , 10, 791-798	3.2	4
44	Opportunistic infections complicating immunotherapy for non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 1689-1694	3.2	4
43	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. <i>OncoTargets and Therapy</i> , 2018 , 11, 7513-7519	4.4	4
42	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.. <i>Thoracic Cancer</i> , 2021 ,	3.2	4
41	Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. <i>Targeted Oncology</i> , 2019 , 14, 325-333	5	3
40	Recognition and management of the gastrointestinal and hepatic immune-related adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020 , 16, 95-102	1.9	3
39	Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?. <i>Oncotarget</i> , 2017 , 8, 86969-86984	3.3	3
38	Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. <i>Thoracic Cancer</i> , 2021 ,	3.2	3
37	Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique. <i>Thoracic Cancer</i> , 2021 , 12, 3157-3168	3.2	3
36	Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient. <i>Frontiers in Immunology</i> , 2021 , 12, 619147	8.4	3
35	Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 2339-2344	3.2	3
34	Pituitary Involvement in Granulomatosis with Polyangiitis: A Retrospective Analysis in a Single Chinese Hospital and a Literature Review. <i>International Journal of Endocrinology</i> , 2019 , 2019, 2176878	2.7	3

33	Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. <i>Thoracic Cancer</i> , 2021 , 12, 2825-2828	3.3	3
32	Detection of low-level DNA mutation by ARMS-blocker-Tm PCR. <i>Clinical Biochemistry</i> , 2016 , 49, 287-91	3.5	2
31	IgG4-related disease can present as recurrent spontaneous hemothorax: a case report. <i>BMC Pulmonary Medicine</i> , 2019 , 19, 26	3.5	2
30	Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib. <i>Thoracic Cancer</i> , 2019 , 10, 1213-1219	3.2	2
29	A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920965849	5.4	2
28	Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. <i>Thoracic Cancer</i> , 2020 , 11, 2339-2342	3.2	2
27	Pulmonary hypertension associated with combined fibrosing mediastinitis and bronchial anthracofibrosis: A retrospective analysis in a single Chinese hospital. <i>Clinical Respiratory Journal</i> , 2018 , 12, 1134-1140	1.7	2
26	ALK-rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report. <i>Thoracic Cancer</i> , 2018 , 9, 1078-1081	3.2	2
25	An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8039-8039	2.2	2
24	Impact of crizotinib on long-term survival of -positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019 , 31, 481-488	3.8	2
23	Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer. <i>ESMO Open</i> , 2020 , 5,	6	2
22	Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21072-e21072	2.2	2
21	International consensus on severe lung cancer-the first edition. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2633-2666	4.4	2
20	Prognostic impact of maximum standardized uptake value on F-FDG PET/CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2021 , 12, 845-853	3.2	2
19	Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). <i>Thoracic Cancer</i> , 2018 , 9, 1795-1800	3.2	2
18	EGFR mutation status in cerebrospinal fluid of NSCLC patients who developed leptomeningeal metastasis after EGFR-TKI treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8081-8081	2.2	1
17	Effect of abundance of EGFR activating mutations and presence of T790M mutation in TKIs-naive tumor specimen on gefitinib response duration in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19077-e19077	2.2	1
16	Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response. <i>Thoracic Cancer</i> , 2021 ,	3.2	1

15	Tumor CD47 expression and a high M2/M1 ratio of tumor-associated macrophages as an adverse prognostic factor in resected stage IIIa non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e20531-e20531	2.2	1
14	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9077-9077	2.2	1
13	Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs. <i>Cancer Medicine</i> , 2021 , 10, 3323-3331	4.8	1
12	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer.. <i>Frontiers in Immunology</i> , 2021 , 12, 749461	8.4	1
11	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis.. <i>Thoracic Cancer</i> , 2022 ,	3.2	1
10	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.. <i>Translational Lung Cancer Research</i> , 2021 , 10, 4477-4493	4.4	1
9	Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib. <i>Cancer Management and Research</i> , 2019 , 11, 8191-8200	3.6	0
8	A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.. <i>Lung Cancer</i> , 2022 , 166, 98-106	5.9	0
7	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 2077-2086	3.2	0
6	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1403-1414	8.9	0
5	Association of PFS with levels of pretreatment lactate dehydrogenase in patients with EML4-ALK rearrangement non-small cell lung cancer treated with ALK tyrosine kinase inhibitor.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20513-e20513	2.2	
4	The pathway of PI3K/AKT/mTOR in pulmonary carcinoids.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22185-e22185		
3	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19070-e19070	2.2	
2	Immunohistochemistry to detect EGFR mutation and ALK gene rearrangement in NSCLC bronchoscopic specimens.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19135-e19135	2.2	
1	Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 879554	5.3	